Lung Cancer CA209370

May 09, 2017

Sponsor: Bristol-Myers Squibb

Number: CA209370

The purpose of this study is to determine whether Nivolumab monotherapy or in combination with Standard of care (SOC) therapies will provide clinical benefit (i.e., PFS, OS, and DOR) without unacceptable toxicity in advanced Non-Small Cell Lung Cancer patients.

Who’s eligible:

  • The patient must have histologically confirmed locally advanced or stage IV NSCLC. Stage IV cancer is non-small cell lung cancer which has spread from the site of the primary (original) tumor only to surrounding tissue.
  • The Eastern Cooperative Oncology Group (ECOG) Performance status (PS) must be 0-2. Tumor tissue sections must be available for biomarker evaluation. ECOG status is used by your doctor in order to assess how your disease is progressing, assess how the disease effects of your daily living abilities, and determine appropriate treatment and prognosis.
  • This study is for patients age 18 and older.

Available at: Backus Hospital- Eastern Connecticut Hematology and Oncology.

Cancer Clinical Research Office